Rheumatoid arthritis is a systemic autoimmune rheumatic disorder of unknown etiology.
It is the most common form of inflammatory arthritis.
Patient usually complains of joint pain and/or swelling with morning stiffness that lasts for more than an hour.
Goals of treatment are clinical and radiological remission of disease and to reduce functional limitations and permanent joint damage.
In patients with early rheumatoid arthritis (RA), vitamin D deficiency is associated with more active and severe disease at baseline and is a predictor of disability and radiographic progression, suggests a study.
For rheumatoid arthritis (RA) patients initiating a new treatment, contactless monitoring via a smartphone application cuts down on office visits while keeping up tight control of disease activity, which in turn boosts general well-being, as shown in a study.
Treatment with E6011, a novel cell trafficking inhibitor targeting the fractalkine (FKN)‐CX3CR1 interaction, confers modest benefits in rheumatoid arthritis (RA), according to the results of a phase II trial.
Dehydroepiandrosterone supplementation confers benefits for quality of life (QoL) but not for disease activity relative to placebo in premenopausal women with rheumatoid arthritis (RA), a study has found.
Ritlecitinib, an oral JAK3/TEC inhibitor, appears to be well tolerated and produce significant improvements disease activity in patients with rheumatoid arthritis, according to the results of a phase II study.
More than half of rheumatoid arthritis (RA) patients achieving low disease activity on long-term methotrexate (MTX) remain flare-free following its withdrawal, as shown in a study. The use of a higher MTX dose to preserve low disease activity is predictive of disease flare after discontinuation.
The Janus kinase inhibitors tofacitinib 10 mg and peficitinib 150 mg prove to be the most effective regimens in the treatment of patients with refractory rheumatoid arthritis (RA) receiving methotrexate (MTX), without increasing the risk of serious adverse events, according to the results of a network meta-analysis.
Dr. Hsu Li Yang, Dr. Tan Thuan Tong, Dr. Andrea Kwa,
08 Jan 2021
Antimicrobial resistance has become increasingly dire as the rapid emergence of drug resistance, especially gram-negative pathogens, has outpaced the development of new antibiotics. At a recent virtual symposium, Dr Hsu Li Yang, Vice Dean (Global Health) and Programme Leader (Infectious Diseases), NUS Saw Swee Hock School of Public Health, presented epidemiological data on multidrug-resistant (MDR) gram-negative bacteria (GNB) in Asia, while Dr Tan Thuan Tong, Head and Senior Consultant, Department of Infectious Diseases, Singapore General Hospital (SGH), focused on the role of ceftazidime-avibactam in MDR GNB infections. Dr Andrea Kwa, Assistant Director of Research, Department of Pharmacy, SGH, joined the panel in an interactive fireside chat, to discuss challenges, practical considerations, and solutions in MDR gram-negative infections. This Pfizer-sponsored symposium was chaired by Dr Ng Shin Yi, Head and Senior Consultant of Surgical Intensive Care, SGH.
Spending too much time sitting cannot be good for the body, and rising to one's feet breaks up such a behaviour and yields small, but meaningful, reductions in certain cardiovascular disease (CVD) risk factors, according to the results of a meta-analysis.
Use of thyroid hormone therapy does not seem to protect older adults with subclinical hypothyroidism against mortality, but it appears to confer survival benefits to those aged <65 years, results of a study have shown.